Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
AGIOS PHARM (NASDAQ: AGIO) Delayed: 36.28 +0.23 (0.64%)
Previous Close $36.05    52 Week High $71.49 
Open $35.13    52 Week Low $33.50 
Day High $36.68    P/E N/A 
Day Low $35.09    EPS $-1.18 
Volume 778,073